IL1A and psoriasis: Data from earlier phase clinical studies in hidradentitis suppurativa [25] and psoriasis [23] using bermekimab revealed significant therapeutic activity with the IL-1⍺ target, and bermekimab monoclonal antibody therapy appeared to be effective at specifically targeting IL-1α in addition to reducing the severity of AD, including rapid reduction in itch and pain.